Drug Profile
ReS18 H
Alternative Names: ReS 18-HLatest Information Update: 17 Jul 2023
Price :
$50
*
At a glance
- Originator reMYND
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Huntington's disease
Most Recent Events
- 17 Jul 2023 ReS 18 H is still in preclinical development for Huntington's disease in Belgium (reMYND Pipeline, July 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Huntington's-disease in Belgium
- 21 Jul 2016 Preclinical trials in Huntington's disease in Belgium (unspecified route)